Candida albicans: Morphology, Pathogenesis, Diagnosis, Treatment, and Prevention

Table of Contents

• Introduction to Candida albicans
• Habitat of Candida albicans
• Morphology of Candida albicans
• Cultural Characteristics of Candida albicans
• Life Cycle of Candida albicans
• Pathogenesis of Candida albicans
• Virulence Factors of Candida albicans
• Lab Diagnosis of Candida albicans
• Treatments of Candida albicans
• Prevention and Control of Candida albicans
• References

Ready Made Presentation

Introduction to Candida albicans

• Candida albicans is a common opportunistic fungal pathogen found in humans.
• It is a part of the normal microbiota of the mouth, gastrointestinal tract, and vagina.
• It usually lives harmlessly in the body under normal conditions.
• Overgrowth occurs when the immune system is weakened or normal flora is disturbed.
• It is a dimorphic fungus, meaning it can exist in both yeast and filamentous (hyphal) forms.
• The ability to switch forms contributes to its pathogenicity.
• It reproduces mainly by budding in its yeast form.
• It can form biofilms on medical devices and tissues.
• It is one of the most common causes of fungal infections in humans.
• Infections caused by it are known as candidiasis.
• It commonly causes oral thrush, vaginal infections, and systemic infections.
• Risk factors include antibiotic use, diabetes, immunosuppression, and poor hygiene.
• It can invade tissues and enter the bloodstream in severe cases.
• It is widely studied in microbiology due to its clinical importance.

Habitat of Candida albicans

• Candida albicans is commonly found on mucosal membranes of humans and other warm-blooded animals.
• It naturally inhabits the oral cavity, gastrointestinal tract, and vagina.
• It can also be present on the surface of the skin.
• It exists as a normal commensal organism under healthy conditions.
• It is found in the digestive tract of birds as well.
• It can be isolated from environmental sources such as soil.
• It is also detected in animals and hospital environments.
• It may be present on inanimate objects and contaminated surfaces.
• It can occasionally be found in food sources.
• It has a worldwide distribution and is found globally.

Morphology of Candida albicans

• Candida albicans cells are small and oval in shape, measuring about 2–4 µm in diameter.
• It exists in a yeast form which is unicellular.
• It reproduces mainly by budding.
• Single budding of the cells is commonly observed.
• Both yeast cells and pseudohyphae appear Gram-positive on staining.
• It is an encapsulated and diploid organism.
• It can also form true hyphae under certain conditions.
• It is a polymorphic fungus showing yeast and pseudohyphal forms.
• It has the ability to form biofilms on surfaces.
• Under normal conditions, it exists primarily in the yeast form.
• Under special conditions such as changes in pH and temperature, it forms pseudohyphae.
• Its cell wall is composed of about 80–90% carbohydrates.

Cultural Characteristics of Candida albicans

Sabouraud Dextrose Agar (SDA)

• Creamy, smooth, and pasty colonies are observed.
• Colonies develop within 24–48 hours.
• Growth occurs at 25–37°C.
• Colonies appear white to cream in color.
• Yeast-like characteristic odour is present.

Blood Agar

• Colonies appear white to creamy in color.
• Smooth and slightly raised colonies are formed.
• Characteristic foot-like extensions may be seen from the margins.
• Growth is visible within 24–48 hours.

Potato Dextrose Agar (PDA)

• Smooth and creamy colonies are formed.
• Colonies develop within 24–48 hours.
• Growth appears moist and glistening.

CHROMagar Candida

• Colonies appear green in color.
• Helps in differentiation from other Candida species.
• Colonies are smooth and well-defined.
• Useful for rapid identification in clinical laboratories.

Life Cycle of Candida albicans

• It reproduces asexually and does not undergo true meiosis.
• It shows three distinct morphological forms: yeast, pseudohyphae, and true hyphae.
• It follows a parasexual life cycle instead of a typical sexual cycle.
• It has the ability to switch between different phenotypes.
• Efficient mating requires diploid cells of opposite mating types.
• These cells must switch from the “white” phase to the “opaque” phase before mating.
• After switching, cell fusion occurs between compatible cells.
• This fusion results in the formation of tetraploid cells.
• Tetraploid cells return to the diploid state through chromosome loss.
• This process occurs without meiosis and is called a parasexual cycle.
• White form consists of round, smooth cells forming dome-shaped colonies.
• Opaque form consists of elongated cells forming flatter colonies.
• Opaque form is more efficient for mating compared to the white form.

Pathogenesis of Candida albicans

• It is an opportunistic fungal pathogen that causes candidiasis in humans.
• It normally exists as a commensal but becomes pathogenic under favorable conditions.
• Infection commonly occurs in immunocompromised individuals.
• High-risk groups include HIV-infected patients, transplant recipients, and chemotherapy patients.
• It can overgrow when normal microbiota is disrupted, such as after antibiotic use.
• It adheres to host tissues and forms biofilms, enhancing its virulence.
• It can invade tissues by switching from yeast to hyphal form.
• It produces enzymes that help in tissue invasion and damage.

Mode of Transmission

• It can be transmitted from mother to infant during childbirth.
• Sexual transmission is rare but possible.
• Person-to-person transmission may occur in hospital settings, especially via contaminated hands or surfaces.

Virulence Factors of Candida albicans

• Polymorphism is a key virulence factor showing yeast, pseudohyphae, and hyphal forms.
• Hyphal form is more important for tissue invasion and infection.
• Adhesins such as Als3 protein help in attachment to host surfaces.
• These are glycosylphosphatidylinositol (GPI)-linked cell surface glycoproteins.
• They also play an important role in biofilm formation.
• Invasins like Als3 protein promote invasion into epithelial and endothelial cells.
• Ssa1 encodes a heat shock protein that induces host cells to engulf the fungus.
• Active penetration into host cells occurs through hyphal formation.
• Biofilm formation enhances survival and resistance.
• Sequence includes yeast adhesion → surface colonization → hyphal development → mature biofilm → dispersion of yeast cells.
• Transcription factors such as Bcr1, Tec1, and Efg1 regulate biofilm formation.
• Secreted hydrolases include proteases, phospholipases, and lipases.
• These enzymes help in tissue invasion and nutrient acquisition.
• Includes Sap 1–10 proteases, multiple phospholipases, and LIP 1–10 lipases.
• Metabolic adaptation allows survival in different host environments.
• It can switch between glycolysis and starvation responses.
• Activation of the glyoxylate cycle supports survival in nutrient-limited conditions.
• This adaptability allows spread to multiple organs via bloodstream.

Stages of Infection

• Colonization involves epithelial adhesion and nutrient acquisition.
• Superficial infection includes epithelial penetration and host protein degradation.
• Deep-seated infection involves tissue penetration, vascular invasion, and immune evasion.
• Disseminated infection includes endothelial adhesion and spread to other organs.
• It may activate coagulation and blood clotting cascades.

Types of Candidiasis

Mucosal Candidiasis

• Oral candidiasis affects the mucous membranes of the mouth.
• Denture-related stomatitis causes inflammation under dentures.
• Angular cheilitis causes cracks at the corners of the mouth.
• Median rhomboid glossitis leads to loss of tongue papillae.
• Vulvovaginitis causes white lesions in vulva, vagina, and cervix.
• Balanitis affects the glans penis.
• Esophageal candidiasis causes painful swallowing.

Cutaneous Candidiasis

• Candida folliculitis causes infection of hair follicles.
• Candidal intertrigo affects skin folds.
• Candidal paronychia involves nail fold inflammation.
• Perianal candidiasis affects skin around the anus.
• Chronic mucocutaneous candidiasis is linked to T-cell immune defects.
• Congenital cutaneous candidiasis occurs in newborns.
• Diaper candidiasis affects the diaper area in infants.
• Erosio interdigitalis blastomycetica affects skin between fingers.
• Candidal onychomycosis causes nail infection.

Systemic Candidiasis

• Candidemia can lead to sepsis.
• Disseminated candidiasis affects multiple organs.
• Endocarditis involves infection of the heart lining.
• Gastrointestinal tract infection may occur.
• Respiratory tract infection can develop.
• Genitourinary candidiasis affects urinary and genital systems.
• Hepatosplenic candidiasis is a chronic disseminated infection affecting liver and spleen.

Lab Diagnosis of Candida albicans

Specimens

• Clinical samples include exudates, tissues, and skin or mucosal scrapings.

Microscopy (Scrapings)

• Wet mount examination is done using 10% KOH preparation.
• Pseudohyphae and budding yeast cells are observed.
• Gram staining shows Gram-positive (+ve) yeast cells.

Culture

• On Sabouraud Dextrose Agar (SDA), creamy white, smooth colonies are formed.
• On CHROMagar, characteristic green-colored colonies appear.

Identification Tests

• Germ tube test is positive within 2 hours when incubated in human serum at 37°C.
• Chlamydospores are produced on corn meal or rice agar at 25°C.
• These are round, thick-walled structures formed terminally or laterally.

Biochemical Tests

• Glucose and maltose are fermented with acid and gas production.
• Sucrose and lactose are not fermented.
• Pale pink coloration appears in tetrazolium reduction medium.

Serology

• Has limited specificity due to widespread exposure.
• Serum antibodies and cell-mediated immunity are present in most individuals.
• Delayed hypersensitivity skin test indicates cell-mediated immunity (CMI).
• ELISA and RIA detect circulating Candida antigens such as mannan.

1,3-beta-D-glucan Assay

• Detects beta-D-glucan, a component of the fungal cell wall.
• Works by activation of factor G in the horseshoe crab coagulation cascade.
• It is a highly sensitive and specific diagnostic test.

Molecular Methods

• DNA probe techniques are used for detection.
• PCR provides rapid and accurate identification.

Treatments of Candida albicans

Oral Candidiasis

• Treated with antifungal agents such as Nystatin.
• Topical azoles like Miconazole are commonly used.
• Severe cases may require Amphotericin B.

Cutaneous Candidiasis

• Treated with topical antifungals such as Clotrimazole and Econazole.
• Other options include ciclopirox, ketoconazole, miconazole, and nystatin.

Systemic and Oral Azoles

• Common drugs include Fluconazole.
• Alternatives include Itraconazole and Posaconazole.

Vulvovaginal Candidiasis

• Single-dose oral Fluconazole is effective.
• Topical antifungals include butoconazole, clotrimazole, miconazole, nystatin, ticonazole, and terconazole.

Bloodstream Infections

• Treated with intravenous Fluconazole.
• Echinocandins such as Caspofungin are also used.

Candidemia

• Managed with Fluconazole or Anidulafungin.
• Early treatment is important to prevent systemic complications.

Prevention and Control of Candida albicans

• Maintain a healthy lifestyle to support a strong immune system.
• Practice good hygiene and proper personal care.
• Ensure a balanced diet with proper nutrition.
• Use antibiotics carefully to avoid disrupting normal microbiota.
• Include probiotics in the diet to support beneficial microorganisms.
• Reduce sugar intake to limit fungal overgrowth.
• Wear cotton underwear and loose-fitting clothing.
• Change wet or damp clothes immediately to prevent fungal growth.

References

• Barantsevich, N., & Barantsevich, E. (2022). Diagnosis and treatment of invasive candidiasis. Antibiotics, 11(718). https://doi.org/10.3390/antibiotics11060718
• Calderone, R., & Fonzi, W. (2001). Virulence factors of Candida albicans. Trends in Microbiology, 9(7), 327–335. https://doi.org/10.1016/s0966-842x(01)02094-7
• Dadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018). Candida albicans: Biology, molecular characterization, pathogenicity, and advances in diagnosis and control—An update. Microbial Pathogenesis, 117, 128–138. https://doi.org/10.1016/j.micpath.2018.02.028
• Faustino, M., Ferreira, C., Pereira, A., & Carvalho, A. (2025). Candida albicans: The current status regarding vaginal infections. Applied Microbiology and Biotechnology, 109. https://doi.org/10.1007/s00253-025-13478-2
• Kim, J., & Sudbery, P. (2011). Candida albicans, a major human fungal pathogen. Journal of Microbiology, 49, 171–177. https://doi.org/10.1007/s12275-011-1064-7
• Kumamoto, C., Gresnigt, M., & Hube, B. (2020). The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Current Opinion in Microbiology, 56, 7–15. https://doi.org/10.1016/j.mib.2020.05.006
• Lopes, J., & Lionakis, M. (2021). Pathogenesis and virulence of Candida albicans. Virulence, 13, 89–121. https://doi.org/10.1080/21505594.2021.2019950
• Martins, N., Ferreira, I., Barros, L., Silva, S., & Henriques, M. (2014). Candidiasis: Predisposing factors, prevention, diagnosis, and alternative treatment. Mycopathologia, 177, 223–240. https://doi.org/10.1007/s11046-014-9749-1
• Mayer, F., Wilson, D., & Hube, B. (2013). Candida albicans pathogenicity mechanisms. Virulence, 4, 119–128. https://doi.org/10.4161/viru.22913
• Parambath, S., Dao, A., Kim, H., Zawahir, S., Izquierdo, A., Tacconelli, E., Govender, N., Oladele, R., Colombo, A., Sorrell, T., Ramon-Pardo, P., Fusire, T., Gigante, V., Sati, H., Morrissey, C., Alffenaar, J., & Beardsley, J. (2024). Candida albicans—A systematic review to inform the WHO Fungal Priority Pathogens List. Medical Mycology, 62. https://doi.org/10.1093/mmy/myae045
• Pereira, R., Fontenelle, R., De Brito, E., & De Morais, S. (2020). Biofilm of Candida albicans: Formation, regulation, and resistance. Journal of Applied Microbiology, 131. https://doi.org/10.1111/jam.14949
• Pereira, L., Correia, A., Da Silva, Z., De Resende, C., Brandão, F., Almeida, R., & De Medeiros Nóbrega, Y. (2021). Vulvovaginal candidiasis and current perspectives: New risk factors and laboratory diagnosis using MALDI-TOF. European Journal of Clinical Microbiology & Infectious Diseases, 40, 1681–1693. https://doi.org/10.1007/s10096-021-04199-1
• Rodríguez-Cerdeira, C., Gregorio, M., Molares-Vila, A., López-Barcenas, A., Fabbrocini, G., Bardhi, B., Sinani, A., Sánchez-Blanco, E., Arenas-Guzmán, R., & Hernández-Castro, R. (2019). Biofilms and vulvovaginal candidiasis. Colloids and Surfaces B: Biointerfaces, 174, 110–125. https://doi.org/10.1016/j.colsurfb.2018.11.011
• Sahoo, B., Goyal, R., Dutta, S., Joshi, P., & Sanyal, K. (2025). Candida albicans: Insights into the biology and experimental innovations of a commonly isolated human fungal pathogen. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c00079
• Silva, K., Nascimento, G., Da Silva, E., Cabral, L., Faria, T., & Oliveira, J. (2024). Candida albicans: Virulence factors, pathogenesis, and ways to diagnose and control infection. Research, Society and Development, 13(1). https://doi.org/10.33448/rsd-v13i1.44781
• Staniszewska, M. (2020). Virulence factors in Candida species. Current Protein & Peptide Science. https://doi.org/10.2174/1389203720666190722152415
• Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., & Škrlec, I. (2021). Candida albicans—The virulence factors and clinical manifestations of infection. Journal of Fungi, 7(79). https://doi.org/10.3390/jof7020079
• Valentine, M., Wilson, D., Gresnigt, M., & Hube, B. (2025). Vaginal Candida albicans infections: Host–pathogen–microbiome interactions. FEMS Microbiology Reviews, 49. https://doi.org/10.1093/femsre/fuaf013
• Whiteway, M., & Bachewich, C. (2007). Morphogenesis in Candida albicans. Annual Review of Microbiology, 61, 529–553. https://doi.org/10.1146/annurev.micro.61.080706.093341